Perindopril treatment in the prevention of stroke in experimental animals

被引:0
作者
Lee, RMKW
Wang, H
Smeda, JS
机构
[1] MCMASTER UNIV, FAC HLTH SCI,SMOOTH MUSCLE RES PROGRAMME, HAMILTON, ON, CANADA
[2] MEM UNIV NEWFOUNDLAND, FAC MED,DIV BASIC MED SCI, St John, NF A1B 3V6, CANADA
关键词
stroke; perindopril; blood pressure; myogenic response; cerebral artery;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective To determine the effect of perindopril treatment and treatment withdrawal in the prevention of stroke in male stroke-prone spontaneously hypertensive rats (SPSHR). Design After weaning at 4 weeks of age, male SPSHR were given a Japanese-style rat diet which induces stroke in these animals. Beginning at 6 weeks of age, SPSHR were treated with either distilled water (control) or different daily dosages of perindopril (1 or 4 mg/kg) by gavage for 24 weeks followed by treatment withdrawl. Additional subgroups were treated with the 4 mg/kg dose for different durations (8, 12 or 24 weeks) before treatment withdrawal. Treatment effects on blood pressure, heart rate and body weight were studied during the treatment period and after the withdrawal of the treatment. Myogenic and mechanical properties of the middle cerebral arteries were studied in control SPSHR that had developed stroke, in treated SPSHR at the end of the treatment period, and at certain intervals after the withdrawal of the treatment. Methods Systolic blood pressure, heart rate and body weight of control and treated SPSHR were determined at regular intervals before, during and after the treatment withdrawal periods until they died from stroke, or until 42 or 43 weeks of age when the study was terminated. Functional studies of the cerebral arteries were carried out using a pressurized artery system. At necropsy, macroscopic and microscopic examinations were made of the kidneys and brain. Results Untreated SPSHR usually died of stroke-related complications by 14 weeks of age. The middle cerebral arteries from these animals had lost their ability to contract in response to pressure increase. Chronic treatment of SPSHR with perindopril when initiated at 6 weeks of age attenuated the sharp blood pressure rise, and prevented the development of stroke during the treatment period. This was associated with the preservation of the myogenic response of the middle cerebral arteries to pressure increase, and the prevention of tissue damage in the kidneys and brain. After withdrawl of the treatment, SPSHR treated for a longer period (12 or 24 weeks) also survived longer than those treated for a shorter period (8 weeks). The subsequent loss of myogenic response in the middle cerebral arteries was associated with the development of stroke and death in these treatment withdrawl groups. Conclusion Chronic treatment with perindopril is beneficial for the prevention of stroke in SPSHR, through the preservation of the myogenic response properties of the cerebral arteries, and the attenuation of tissue damage in the brain and kidneys.
引用
收藏
页码:S29 / S33
页数:5
相关论文
共 50 条
  • [41] PROGRESS - Perindopril protection against recurrent stroke study: Status in July 1996
    Chalmers, J
    Macmahon, S
    Bousser, MG
    Cutler, J
    Donnan, G
    Hansson, L
    Harrap, S
    Liu, LS
    Mancia, G
    Menard, J
    Omae, T
    Reid, J
    Rodgers, A
    Warlow, C
    Culpan, A
    Currie, R
    Flett, S
    Neal, B
    Milne, A
    Davis, S
    Gong, LS
    Sega, R
    Yamaguchi, T
    Terent, A
    Lees, K
    Williams, F
    Wang, JG
    Wang, W
    Biousse, V
    Tzourio, C
    Crespi, S
    Fujimoto, K
    Marttala, K
    Fenton, J
    McIlvenna, Y
    JOURNAL OF HYPERTENSION, 1996, 14 : S47 - S51
  • [42] Stroke in patients with diabetes mellitus:: prevention and treatment
    Roether, J.
    DIABETES STOFFWECHSEL UND HERZ, 2007, 16 (04): : 291 - 296
  • [43] Stroke in Women: Recognizing Opportunities for Prevention and Treatment
    Kaplovitch, Eric
    Anand, Sonia S.
    STROKE, 2018, 49 (03) : 515 - 517
  • [44] Current Status of Dyslipidemia Treatment for Stroke Prevention
    Aradine, Elizabeth
    Hou, Yan
    Cronin, Carolyn A.
    Chaturvedi, Seemant
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2020, 20 (08)
  • [45] Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke
    Kikuchi, Kiyoshi
    Uchikado, Hisaaki
    Morioka, Motohiro
    Murai, Yoshinaka
    Tanaka, Eiichiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (06) : 7739 - 7761
  • [46] Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
    Herrington, William
    Haynes, Richard
    Staplin, Natalie
    Emberson, Jonathan
    Baigent, Colin
    Landray, Martin
    SEMINARS IN DIALYSIS, 2015, 28 (01) : 35 - 47
  • [47] Stroke: development, prevention and treatment with peptidase inhibitors
    Mark, KS
    Davis, TP
    PEPTIDES, 2000, 21 (12) : 1965 - 1973
  • [48] Race/Ethnicity Considerations in the Prevention and Treatment of Stroke
    Forman, Rachel
    Sheth, Kevin
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2021, 23 (09)
  • [49] Current Status of Dyslipidemia Treatment for Stroke Prevention
    Elizabeth Aradine
    Yan Hou
    Carolyn A. Cronin
    Seemant Chaturvedi
    Current Neurology and Neuroscience Reports, 2020, 20
  • [50] From Preclinical Stroke Models to Humans: Polyphenols in the Prevention and Treatment of Stroke
    Parrella, Edoardo
    Gussago, Cristina
    Porrini, Vanessa
    Benarese, Marina
    Pizzi, Marina
    NUTRIENTS, 2021, 13 (01) : 1 - 38